Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 7/20 | 0.40 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783164 | 0.91 | TSHR (0.42) | TSHRHTR6CNR2L3MBTL1 | |
| SCHEMBL4782487 | 0.85 | HTR6 (0.48) | SIGMAR1ALOX15TSHRHTR6SFRP1 | |
| SCHEMBL14209100 | 0.85 | SIGMAR1 (0.43) | SIGMAR1ALOX15TSHRHTR6SFRP1 | |
| SCHEMBL4785354 | 0.82 | MAPK1 (0.41) | HTR6 | |
| SCHEMBL4783597 | 0.79 | TDP1 (0.51) | TSHRHTR6L3MBTL1 | |
| SCHEMBL4784058 | 0.79 | HTR6 (0.41) | TSHRHTR6 | |
| SCHEMBL4783077 | 0.77 | TBXAS1 (0.46) | — | |
| SCHEMBL14208706 | 0.76 | TSHR (0.44) | TSHRHTR6 | |
| SCHEMBL4781382 | 0.75 | HTR6 (0.43) | TSHRHTR6 | |
| SCHEMBL4783123 | 0.75 | HTR6 (0.45) | TSHRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008060998-A1 | INDOLE SULFONAMIDES AS SFRP-1 MODULATORS | WYETH (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2008060998-A1 | INDOLE SULFONAMIDES AS SFRP-1 MODULATORS | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |